股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 京东健康股份有限公司 呈交日期: 2025年12月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06618 | | 說明 | | | | | | | | | 多櫃檯證券代號 | 86618 | RMB | 說明 | | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | | 100,000,000,000 | USD | | 0.0000005 | USD | | 50,000 | | 增加 / 減少 (-) | | | | 0 | | | | USD | | 0 | | 本月底結 ...

Core Insights - JD Health has entered into a strategic partnership with Qingdao Haifa Health Investment Holding Company to obtain the dual natural all-channel agency rights for the product An Gong Niu Huang Wan, marking a deeper engagement in the pharmaceutical supply chain sector [1][3] - The collaboration aims to expand the product's market presence both online and offline, creating new growth opportunities for JD Health [1] Group 1 - JD Health will provide a comprehensive all-channel agency sales solution for An Gong Niu Huang Wan, leveraging its integrated online and offline pharmaceutical supply chain service system to reach a broader market and user base [1] - This partnership enhances JD Health's integrated operations and refined management capabilities, while also strengthening its customized supply chain service capabilities [1][3] Group 2 - JD Health's pharmaceutical business leader emphasized the company's commitment to leveraging its "super pharmaceutical supply chain" capabilities, integrating digital and intelligent technologies to improve pharmaceutical distribution efficiency and healthcare service experiences [3] - Qingdao Haifa Health's leader stated that the company focuses on the life and health industry and aims to leverage its resources in collaboration with JD Health for mutual benefits and complementary advantages [3] - JD Health has established an integrated marketing and service system covering both online and offline channels, enabling efficient matching of pharmaceuticals with potential demand groups through user insights and precise marketing capabilities [3]

(本文来自第一财经) 来源：第一财经 恒生指数高开0.17%，恒生科技指数涨0.21%。京东健康、紫金矿业、携程集团涨逾3%；新能源车概念 股再度走低，理想汽车、小鹏汽车、蔚来均下跌。 ...

Core Insights - JD Health announced three core strategies for sustainable growth in the nutrition and health industry: user experience optimization, quality supply enhancement, and efficient brand growth [1][3] - The launch of the "S100 Project" aims to enhance collaboration with brand partners across four dimensions: products, marketing, experience, and mechanisms to achieve long-term growth [1][9] Industry Overview - The nutrition and health market in China is projected to exceed 400 billion yuan by 2025, driven by a shift in consumer focus from "treating illness" to "preventing illness" [3] - JD Health's market share continues to grow due to its solid supply chain and professional service capabilities [3] User Experience and Service - JD Health has introduced a unique "Nutritionist + AI Nutritionist" service matrix, which has served 20 million users this year with a sales conversion rate of 45% [5] - The company is committed to creating a user-friendly shopping environment for health products, ensuring a "simple selection and reliable use" experience [3] Product Supply and Standards - JD Health is enhancing its product offerings by focusing on high-potential areas such as infant development, senior nutrition, anti-inflammation, and convenient nutrition [7] - The company is developing an evidence-based nutrition evaluation system to ensure safe and effective health solutions for consumers [6] Marketing and Brand Growth - Over 7,000 nutrition and health brands have achieved sales growth for three consecutive years, with new user numbers increasing by 30% and new product sales rising by 40% [9] - JD Health plans to double its marketing investment to 1.6 billion yuan in 2026, focusing on various marketing initiatives to enhance brand visibility and sales conversion [11]

Core Insights - JD Health has announced three core strategies focused on user experience, quality supply, and brand growth, alongside the launch of the "S100 Project" [1][2] Group 1: Strategic Initiatives - The "S100 Project" aims to gather top-quality brands in the nutrition and health industry, focusing on product, marketing, experience, and mechanisms to leverage more platform resources for brand growth by 2026 [1][2] - JD Health plans to increase its marketing investment to 1.6 billion in 2026, enhancing initiatives like the "Doubling Plan," "Ten Million New Products," and five major marketing IPs including celebrity and scenario marketing [1][2] Group 2: Industry Performance - Over 7,000 nutrition and health brands have achieved continuous sales growth for three consecutive years, with new user numbers in the category increasing by 30% year-on-year since 2025, and new product sales rising by 40% [1][2] - The company emphasizes the need for deep collaboration and value co-creation across the entire industry chain to ensure sustainable growth in the nutrition and health sector [1][2]

Core Insights - JD Health and Boehringer Ingelheim Animal Health (Shanghai) Co., Ltd. signed a strategic cooperation agreement to enhance the pet health industry in China through resource integration and complementary advantages [1][2] - The partnership aims to improve supply chain efficiency and business growth quality by optimizing cooperation models and enhancing brand performance in e-commerce channels [1][2] - JD Health has established a comprehensive pet health service ecosystem covering "medical, testing, pharmaceuticals, and insurance," with a significant increase in pet medicine sales [2] Group 1 - JD Health's strategic cooperation with Boehringer Ingelheim will leverage JD's "super pharmaceutical supply chain" and extensive medical service resources [1] - The collaboration will focus on all-channel supply chain, brand co-construction, and user service [1] - Boehringer Ingelheim's innovative oral external parasite control product, Fuweien, led the pet health category on JD Health for 21 consecutive days after its exclusive online launch [1] Group 2 - JD Health has the most comprehensive online pet medicine supply chain, covering 132 pet medicine approvals and core categories such as deworming and prescription drugs [2] - The platform has over 5,500 licensed veterinarians and offers online doctor education services to effectively communicate brand concepts and product advantages [2] - The partnership is expected to drive sales growth and optimize the pet health industry ecosystem [2] Group 3 - JD Health plans to continue collaborating with global pharmaceutical companies to enhance its pet health product and service matrix [3] - The focus will be on building an efficient and professional pet pharmaceutical distribution system [3] - The commitment to providing convenient and professional health solutions for pet-owning families will be upheld [3]

Group 1 - FTSE Russell announced the new candidate stocks for the FTSE China 50 Index, which include China Aluminum (601600)(02600), Hansoh Pharmaceutical (03692), Huatai Securities (601688)(06886), JD Health (06618), and New China Life Insurance (601336)(01336) [1] - On December 3, FTSE Russell announced adjustments to the FTSE China 50 Index, FTSE China A50 Index, FTSE China A150 Index, FTSE China A200 Index, and FTSE China A400 Index, effective after the market close on December 19, 2025 [2] - The adjustments will include the addition of China Hongqiao (01378), CATL (300750)(03750), and Heng Rui Medicine (600276)(01276) to the FTSE China 50 Index, while removing CITIC Securities H-share (06066), Great Wall Motor H-share (02333), and Li Auto-W (02015) [2]

Core Insights - The health supplement market in China is rapidly expanding, with projections indicating it will exceed 400 billion RMB by 2025, driven by increasing health awareness among consumers [1][4] - Online sales channels have surged, now accounting for nearly 60% of the market share, surpassing traditional channels like direct sales and supermarkets [1] - Trust and quality are becoming critical in the competitive landscape of health supplements, as consumers face information asymmetry and marketing noise [2][11] Market Trends - JD Health reported that its annual repurchase rate for health supplements significantly exceeds the industry average, with a third-quarter growth rate three times that of the projected annual growth for 2024 [2][4] - Over 7,000 brands have experienced sales growth for three consecutive years, with new user numbers increasing by 30% and new product sales rising by 40% [4] Consumer Behavior - Consumers are increasingly discerning, focusing on ingredients, efficacy, and scientific backing rather than just price when selecting health supplements [5][9] - The introduction of AI nutritionists has improved user experience, with 95% of professional consultations now handled by AI, serving over 20 million users annually [7][21] Product Development and Standards - JD Health is establishing an evidence-based nutrition system to evaluate health supplements, ensuring they meet standards of "good ingredients, good manufacturing, and good absorption" [9][19] - The company is collaborating with brands to develop new products based on consumer insights, leading to successful launches such as high-purity fish oil and probiotics [19][20] Marketing and User Engagement - JD Health's marketing strategy includes initiatives like the "S100 project," which focuses on building long-term partnerships with top brands, providing significant resource support for marketing and product launches [19][21] - The company is enhancing user engagement through personalized marketing strategies, aiming to convert potential customers into loyal users [14][21] Supply Chain and Logistics - JD Health is leveraging its supply chain capabilities to improve logistics for cross-border health products, significantly reducing delivery times and costs [10][21] - The company plans to invest 1.6 billion RMB in marketing resources for 2026, focusing on key areas such as children's nutrition and anti-aging products [20][21]

Core Viewpoint - FTSE Russell announced adjustments to several indices including the FTSE China 50 Index, which will take effect after market close on December 19, 2025 [1] Group 1: Index Adjustments - The FTSE China 50 Index will include new constituents such as China Hongqiao (01378), CATL (03750), and Heng Rui Pharmaceutical (01276) [1] - The index will exclude companies like CITIC Securities H (06066), Great Wall Motors H (02333), and Li Auto-W (02015) [1] Group 2: Alternative Stocks - FTSE Russell released a list of alternative stocks for the FTSE China 50 Index, which includes companies like Aluminum Corporation of China (02600), Hansoh Pharmaceutical (03692), Huatai Securities (06886), JD Health (06618), and New China Life Insurance (01336) [1]

Group 1 - The flu season has seen a significant increase in cases, with flu-related medication sales on JD's platform rising by 242% from November 24 to 30 compared to the previous week, particularly in Guangdong, Jiangsu, and Shanghai [1] - Specific medications such as Sufuda saw a 230% increase in sales, Kewai increased by 310%, and flu test kits surged by 337% during the same period [1] - The demand for antiviral medications has skyrocketed, with searches for Oseltamivir increasing nearly 500 times compared to last year, and sales of flu medications growing 32 times year-on-year [1] Group 2 - Several domestic antiviral drugs have been launched this year, with three key products debuting on JD Health: Mashu Lashawei on May 16, Angladiwei on June 27, and Masi Luoshawei on October 13 [2] - Sales of Mashu Lashawei increased by 60% week-on-week, while Angladiwei saw a growth of over 2.7 times, and Masi Luoshawei's sales surged over 10 times [2] - The trend of home rapid testing for flu has gained popularity, with a 79.2% increase in orders for respiratory virus testing and a positive detection rate of 71.5% [2] Group 3 - The influx of patients at offline hospitals has led to a peak in consultations, prompting JD Internet Hospital to establish a fever clinic and launch a flu consultation section on December 1 [2] - The online consultation service aims to alleviate pressure on physical hospitals and reduce the risk of cross-infection by providing 24-hour access to top-tier doctors for professional advice and medication guidance [2] - JD's integrated service model combines medical consultation, testing, and medication delivery, creating a closed-loop service for patients [2]